In order to clarify the effect of anti-TNF therapy on MS patients and non-MS autoimmune diseases, genome-wide association studies (GWAS) may help in identifying a link between the specific response to anti-TNF therapy and the presence of the single nucleotide polymorphism in TNF-related genes that may affect TNF signaling. This evidence concerns the gene TNF and myeloid sarcoma.